Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.
Fiche publication
Date publication
août 2023
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier, Pr MASCAUX Céline
Tous les auteurs :
Besse B, Felip E, Campelo RG, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, M Razaq, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G,
Lien Pubmed
Résumé
Patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICB) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). The cancer vaccine OSE2101 may invigorate antitumor-specific immune responses after ICB failure. The objective of ATALANTE-1 was to evaluate its efficacy and safety in these patients.
Mots clés
Advanced NSCLC, Cancer vaccine, Immunotherapy resistance, Quality of Life
Référence
Ann Oncol. 2023 08 1;: